Pelthos Therapeutics Inc. (PTHS)
NYSEAMERICAN: PTHS · Real-Time Price · USD
16.19
-0.32 (-1.91%)
Jul 3, 2025, 1:00 PM - Market closed

Pelthos Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
-----0.2
Cost of Revenue
-0.27--0.390.210.14
Gross Profit
0.27---0.39-0.210.06
Selling, General & Admin
6.566.394.281.930.631.42
Research & Development
1.181.182.58---
Operating Expenses
7.747.576.861.930.631.42
Operating Income
-7.47-7.57-6.86-2.32-0.84-1.35
Interest Expense
-0.29-0.79-0.52-0.14-0-0
Other Non Operating Income (Expenses)
0.040.04---0.69
EBT Excluding Unusual Items
-7.72-8.32-7.38-2.46-0.84-0.66
Legal Settlements
0.360.36----
Other Unusual Items
----0.24-
Pretax Income
-7.36-7.96-7.38-2.46-0.6-0.66
Net Income
-7.36-7.96-7.38-2.46-0.6-0.66
Net Income to Common
-7.36-7.96-7.38-2.46-0.6-0.66
Shares Outstanding (Basic)
1100--
Shares Outstanding (Diluted)
1100--
Shares Change (YoY)
173.25%336.69%193.25%---
EPS (Basic)
-12.40-14.27-57.82-56.48--
EPS (Diluted)
-12.40-14.27-57.82-56.48--
Gross Margin
-----30.69%
Operating Margin
------677.16%
Profit Margin
------330.40%
EBITDA
----1.63--
D&A For EBITDA
---0.69--
EBIT
-7.47-7.57-6.86-2.32-0.84-1.35
Revenue as Reported
-----0.2
Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q